Nand S - Search Results

1

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.

Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, Veerappan R, Rychlik K, Germano E, Stiff P. Nand S, et al. Leuk Lymphoma. 2008 Nov;49(11):2141-7. doi: 10.1080/10428190802451254. Leuk Lymphoma. 2008. PMID: 19021057 Clinical Trial.

2

Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge.

Nand S, Barton K. Nand S, et al. Leuk Lymphoma. 2007 Feb;48(2):215-6. doi: 10.1080/10428190601173117. Leuk Lymphoma. 2007. PMID: 17325875 No abstract available.

3

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.

Nand S, Othus M, Godwin JE, Willman CL, Norwood TH, Howard DS, Coutre SE, Erba HP, Appelbaum FR. Nand S, et al. Blood. 2013 Nov 14;122(20):3432-9. doi: 10.1182/blood-2013-06-506592. Epub 2013 Oct 3. Blood. 2013. PMID: 24092933 Free PMC article. Clinical Trial.

4

Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.

Achille NJ, Othus M, Phelan K, Zhang S, Cooper K, Godwin JE, Appelbaum FR, Radich JP, Erba HP, Nand S, Zeleznik-Le NJ. Achille NJ, et al. Among authors: nand s. Leuk Res. 2016 Mar;42:68-74. doi: 10.1016/j.leukres.2016.01.004. Epub 2016 Jan 15. Leuk Res. 2016. PMID: 26818573 Free PMC article. Clinical Trial.

5

A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all-trans retinoic acid) therapy.

Naeem M, Harrison K, Barton K, Nand S, Alkan S. Naeem M, et al. Among authors: nand s. Eur J Haematol. 2006 Feb;76(2):164-6. doi: 10.1111/j.0902-4441.2005.00583.x. Eur J Haematol. 2006. PMID: 16405439

6

Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia.

Wang ES, Aplenc R, Chirnomas D, Dugan M, Fazal S, Iyer S, Lin TL, Nand S, Pierce KJ, Shami PJ, Vermette JJ, Abboud CN. Wang ES, et al. Among authors: nand s. Leuk Lymphoma. 2020 Aug;61(8):1965-1973. doi: 10.1080/10428194.2020.1742897. Epub 2020 May 20. Leuk Lymphoma. 2020. PMID: 32432489 Free article.

7

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.

Othus M, Thomas I, Wang X, Ariti C, Mehta P, Sydenham M, Hills RK, Burnett AK, Nand S, Assouline S, Michaelis LC, Erba HP, Russell N, Kerr KF, Walter RB, Dennis M. Othus M, et al. Among authors: nand s. Leuk Lymphoma. 2023 Jan;64(1):250-252. doi: 10.1080/10428194.2022.2131416. Epub 2022 Oct 13. Leuk Lymphoma. 2023. PMID: 36226777 Free PMC article. No abstract available.

8

Hypoplastic myelodysplastic syndrome.

Nand S, Godwin JE. Nand S, et al. Cancer. 1988 Sep 1;62(5):958-64. doi: 10.1002/1097-0142(19880901)62:5<958::aid-cncr2820620519>3.0.co;2-p. Cancer. 1988. PMID: 3409176

9

A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes.

Nand S, Sosman J, Godwin JE, Fisher RI. Nand S, et al. Blood. 1994 Jan 15;83(2):357-60. Blood. 1994. PMID: 8286736 Free article. Clinical Trial.

10

A phase II trial of interleukin-2 in myelodysplastic syndromes.

Nand S, Stock W, Stiff P, Sosman J, Martone B, Radvany R. Nand S, et al. Br J Haematol. 1998 Apr;101(1):205-7. doi: 10.1046/j.1365-2141.1998.00672.x. Br J Haematol. 1998. PMID: 9576203 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters